SCILEX HOLDING CO
SCLX evidence brief
What we can confirm
- BioSniper Score:
- 5.9 / 10
- Market Cap:
- $35.2M
- Lead Asset:
- sp-102 (Phase 3)
What it means
What to watch
Prepared research question
What matters most for SCLX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SCLX
SCILEX HOLDING CO (SCLX) is a revenue-generating biopharmaceutical company focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, with three marketed products and three product candidates in development.
Key risk: Liquidity and going concern
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 3 catalysts for SCILEX HOLDING CO.
SCILEX HOLDING CO (SCLX) is a revenue-generating biopharmaceutical company focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, with three marketed products and three product candidates in development.
- Revenue of $7.6M and net loss of -$115.0M for the three months ended June 30, 2026 [sec]
- Cash & equivalents of $0.6M as of June 30, 2026 [sec]
- Shareholders' equity of -$308.3M as of June 30, 2026 [sec]
- Accumulated deficit of $965.1M as of March 31, 2026 [sec_mda]
- Three marketed products: ZTlido, GLOPERBA (launched June 2024), and ELYXYB (launched April 2023 in U.S.) [sec_mda]
What works
- Company has three revenue-generating commercial products (ZTlido, GLOPERBA, ELYXYB) addressing large pain markets [sec_mda]
- Pipeline includes three product candidates: SP-102 (SEMDEXA) in Phase 3 for sciatica, SP-103 in Phase 2 for chronic neck pain, and SP-104 [sec_mda]
- Non-opioid portfolio targets high unmet needs and large market opportunities, potentially differentiating from opioid-based therapies [sec_mda]
- Successful end-of-Phase 2 meeting with FDA for SP-103, with agreed path to NDA [sec_mda]
What to weigh
- Net loss of $115.0M for three months ended June 30, 2026, and accumulated deficit of $965.1M as of March 31, 2026 [sec_mda]
- Cash & equivalents only $0.6M as of June 30, 2026, with management expressing substantial doubt about ability to continue as a going concern for one year [sec_mda]
- Shareholders' equity deeply negative at -$308.3M as of June 30, 2026 [sec]
- Reliance on sole or single source suppliers for commercial and clinical supply of products and raw materials [sec_mda]
From the filings
Quoted directly from source documents.
Company's net loss and accumulated deficit
“We had a net loss of $115.0 million and $44.0 million for the three months ended June 30, 2026 and 2025”
SEC MD&A · August 14, 2026
Cash position and going concern doubt
“As of March 31, 2026, we had cash and cash equivalents of approximately $3.4 million. Our management has concluded that there is substantial doubt about our ability to continue as a going concern for one year after the date that the unaudited condensed consolidated financial statements are issued.”
SEC MD&A · May 20, 2026
Pipeline and Phase 3 initiation for SEMDEXA
“the Company initiated a second Phase 3 study ("SP-102" or "SEMDEXA") in September 2025”
SEC MD&A · August 14, 2026
Catalyst timeline
- 2031-05-10 · Patent_Expiry · LIDOCAINE — Patent expiry for NDA207962 may affect exclusivity of lidocaine-based products.
- 2036-05-27 · Patent_Expiry · CELECOXIB — Patent expiry for NDA212157 may affect exclusivity of celecoxib-based products.
- 2037-12-20 · Patent_Expiry · COLCHICINE — Patent expiry for NDA210942 may affect exclusivity of colchicine-based products.
Risks & what to watch (4)›
Key risks
- Liquidity and going concern — Cash & equivalents only $0.6M as of June 30, 2026; management expressed substantial doubt about ability to continue as a going concern for one year [sec_mda]
- Deeply negative equity — Shareholders' equity of -$308.3M as of June 30, 2026 indicates severe financial distress [sec]
- Single-source supplier dependency — Company relies on sole or single source suppliers for commercial and clinical supply, creating supply chain risk [sec_mda]
- Sustained operating losses — Net loss of $115.0M for three months ended June 30, 2026; accumulated deficit of $965.1M as of March 31, 2026 [sec_mda]
What to watch
- Progress of SP-102 (SEMDEXA) Phase 3 study for sciatica, initiated September 2025 [sec_mda]
- SP-103 NDA submission and potential approval for chronic neck pain following FDA end-of-Phase 2 meeting [sec_mda]
- Commercial performance of GLOPERBA and ELYXYB, especially GLOPERBA ex-U.S. expansion [sec_mda]
- Any further financing or restructuring moves given the liquidity and going concern warning [sec_mda]
Sources: SEC MD&A · Generated October 11, 2026 · How we verify sources →
Run SCILEX HOLDING CO through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available SCILEX HOLDING CO facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$115M
Lead: Phase 3
3 candidates
3 upcoming, next in ~1669d
2 buys · 1 sell (180d)
Catalysts
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
71
Total value held
$5.8M
| Holder | Shares | Value |
|---|---|---|
| armistice capital, llc | 297,706 | $2.0M |
| vanguard capital management llc | 264,050 | $1.8M |
| blackrock, inc. | 102,796 | $685K |
| vanguard fiduciary trust co | 39,658 | $264K |
| renaissance technologies llc | 36,864 | $246K |
| state street corp | 35,376 | $236K |
| xtx topco ltd | 22,606 | $151K |
| ashton thomas private wealth, llc | 17,989 | $120K |
| northern trust corp | 15,033 | $100K |
| morgan stanley | 11,973 | $80K |
Showing top 10 of 71 institutional holders of SCILEX HOLDING CO. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 3.4%
- Days to cover
- 5.8
- Shares short
- 187,953
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SCLX short interestGovernance
Frequently asked questions
What is the AI investment thesis for SCILEX HOLDING CO?
SCILEX HOLDING CO (SCLX) is a revenue-generating biopharmaceutical company focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, with three marketed products and three product candidates in development.
What is SCILEX HOLDING CO's lead drug candidate?
SCILEX HOLDING CO's most advanced tracked candidate is sp-102 (Phase 3) for lumbosacral radicular pain, or sciatica.
What is SCILEX HOLDING CO's next catalyst?
SCILEX HOLDING CO's next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA207962" — expected May 10, 2031.
Who is the CEO of SCILEX HOLDING CO?
Dr. Henry H. Ji Ph.D. is the chief executive officer of SCILEX HOLDING CO (SCLX).
Where is SCILEX HOLDING CO headquartered?
SCILEX HOLDING CO (SCLX) is headquartered in Palo Alto, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.